{2-[2-(2-Octadecanoylamino-ethoxy)-ethoxy]-ethyl}-carbamic acid tert-butyl ester

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: {2-[2-(2-Octadecanoylamino-ethoxy)-ethoxy]-ethyl}-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[2-[2-[2-(octadecanoylamino)ethoxy]ethoxy]ethyl]carbamate
• 化学式: C₂₉H₅₈N₂O₅
• 分子量: 514.79
• InChiKey: SSCNKRWWGNGMAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  36
• 可旋转键数：
  27
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  85.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  {2-[2-(2-Octadecanoylamino-ethoxy)-ethoxy]-ethyl}-carbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 7.5h， 生成 N-[2-[2-[2-[3-[2-[2-[[(2S)-2,5-bis[(2-bromoacetyl)amino]pentanoyl]amino]ethoxy]ethoxy]propanoylamino]ethoxy]ethoxy]ethyl]octadecanamide
  参考文献：
  名称：

  [EN] PEPTIDE CONJUGATES AND METHODS OF USE
  [FR] CONJUGUÉS PEPTIDIQUES ET MÉTHODES D'UTILISATION

  摘要：

  本文披露了包括以下内容的肽共轭物：选择自可调节PYY受体的肽、可调节GLP-1受体和GCG受体的肽、可调节GLP-1受体和GIP受体的肽、以及可调节GLP-1受体的肽；以及连接到肽的稳定剂，在第一个氨基酸和第二个氨基酸处连接。还提供了包括催乳素释放肽的肽共轭物。这些肽共轭物可用于治疗肥胖等疾病。此外，还提供了稳定的催乳素释放肽。

  公开号：

  WO2021113535A1
• 作为产物：
  描述：

  硬脂酸 、 2-(2-(2-氨基乙氧基)乙氧基)乙基氨基甲酸叔丁酯 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以95%的产率得到{2-[2-(2-Octadecanoylamino-ethoxy)-ethoxy]-ethyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  [EN] LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE
  [FR] CONJUGUÉS PEPTIDIQUES DOUBLE GIP/GLP-1 À ACTION PROLONGÉE ET PROCÉDÉS D'UTILISATION

  摘要：

  本文提供了含有双重葡萄糖依赖性胰岛素促泌肽（GIP）和GLP-1受体激动剂的肽和肽共轭物。这些肽可以用于血糖管理和治疗糖尿病、肥胖症、非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）等疾病。

  公开号：

  WO2022257979A1

文献信息

• Design of a Long-Acting and Selective MEG-Fatty Acid Stapled Prolactin-Releasing Peptide Analog
  作者：Elsa Pflimlin、Sam Lear、Candy Lee、Shan Yu、Huafei Zou、Andrew To、Sean Joseph、Van Nguyen-Tran、Matthew S. Tremblay、Weijun Shen

  DOI：10.1021/acsmedchemlett.9b00182

  日期：2019.8.8

  Anorexigenic peptides offer promise as potential therapies targeting the escalating global obesity epidemic. Prolactin-releasing peptide (PrRP), a novel member of the RFamide family secreted by the hypothalamus, shows therapeutic potential by decreasing food intake and body weight in rodent models via GPR10 activation. Here we describe the design of a long-acting PrRP using our recently developed novel multiple ethylene glycol-fatty acid (MEG-FA) stapling platform. By incorporating serum albumin binding fatty acids onto a covalent side chain staple, we have generated a series of MEG-FA stapled PrRP analogs with enhanced serum stability and in vivo half-life. Our lead compound 18-S4 exhibits good in vitro potency and selectivity against GPR10, improved serum stability, and extended in vivo half-life (7.8 h) in mouse. Furthermore, 18-S4 demonstrates a potent body weight reduction effect in a diet-induced obesity (DIO) mouse model, representing a promising long-acting PrRP analog for further evaluation in the chronic obesity setting.
• Hemolytic Effects of Water-Soluble Fullerene Derivatives
  作者：Susanna Bosi、Luigi Feruglio、Tatiana Da Ros、Giampiero Spalluto、Barbara Gregoretti、Michela Terdoslavich、Giuliana Decorti、Sabina Passamonti、Stefano Moro、Maurizio Prato

  DOI：10.1021/jm0497489

  日期：2004.12.1

  A series of water-soluble fullerene C-60 derivatives has been investigated for their cytotoxic and hemolytic properties, with the aim to correlate structure with toxicity. We observed that cationic chains induce significant toxicity while the presence of neutral or anionic moieties did not produce any response in our model. A validation of these experimental observations has been performed by theoretical studies in which hydrophilic and hydrophobic surface areas were correlated quantitatively with hemolytic properties.
• [EN] GLP2 RECEPTOR AGONISTS AND METHODS OF USE<br/>[FR] AGONISTES DU RÉCEPTEUR GLP2 ET MÉTHODES D'UTILISATION
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2021113524A2

  公开（公告）日：2021-06-10

  Peptide conjugates comprising a peptide that modulates the GLP-2 receptor are provided. The peptide conjugates may be used for treating conditions responsive to modulation of the GLP-2 receptor. Further provided are stapled GLP-2 peptide conjugates.
• [EN] PEPTIDE CONJUGATES AND METHODS OF USE<br/>[FR] CONJUGUÉS PEPTIDIQUES ET MÉTHODES D'UTILISATION
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2021113535A1

  公开（公告）日：2021-06-10

  Peptide conjugates comprising a peptide selected from a peptide that modulates the PYY receptor, a peptide that modulates both the GLP-1 receptor and the GCG receptor, a peptide that modulates both the GLP-1 receptor and the GIP receptor, and a peptide that modulates the GLP-1 receptor; and a staple attached to the peptide at a first amino acid and a second amino acid are disclosed herein. Also provided are peptide conjugates comprising prolactin-releasing peptide. The peptide conjugates may be used for treating conditions such as obesity. Further provided are stapled prolactin-releasing peptide.

  本文披露了包括以下内容的肽共轭物：选择自可调节PYY受体的肽、可调节GLP-1受体和GCG受体的肽、可调节GLP-1受体和GIP受体的肽、以及可调节GLP-1受体的肽；以及连接到肽的稳定剂，在第一个氨基酸和第二个氨基酸处连接。还提供了包括催乳素释放肽的肽共轭物。这些肽共轭物可用于治疗肥胖等疾病。此外，还提供了稳定的催乳素释放肽。
• [EN] LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE<br/>[FR] CONJUGUÉS PEPTIDIQUES DOUBLE GIP/GLP-1 À ACTION PROLONGÉE ET PROCÉDÉS D'UTILISATION
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2022257979A1

  公开（公告）日：2022-12-15

  Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

  本文提供了含有双重葡萄糖依赖性胰岛素促泌肽（GIP）和GLP-1受体激动剂的肽和肽共轭物。这些肽可以用于血糖管理和治疗糖尿病、肥胖症、非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）等疾病。